Published results from preclinical work with the company's oral Aurora A angiogenic kinase inhibitor boosted shares of EntreMed Inc., leaving the stock (NASDAQ:ENMD) to close Monday at $1.73, up 34 cents, or 24.5 percent, after trading as high as $1.99.